ALSERES Pharmaceuticals, Inc. (ALSE) and BioAxone Therapeutic Inc. Amend License Agreement for Cethrin(R) and Rho Inhibitor Technology
4/30/2009 10:46:19 AM
More...
|
BioAxone Therapeutic Inc. Licenses Phase II Spinal Cord Injury Drug Cethrin(R) To Boston Life Sciences (BLSI)
1/4/2007 11:58:50 AM
More...
|
BioAxone Therapeutic Inc. Study Demonstrates Positive Interim Results For Spinal Cord Injury
11/27/2006 10:06:57 AM
More...
|
BioAxone Therapeutic Inc. Announces Patients Completed The 6 Week Follow-Up In The Phase I/IIa Trial Of Cethrin(R) For The Treatment Of Acute Spinal Cord Injury
9/19/2006 2:20:20 PM
More...
|
BioAxone Therapeutic Inc. Completes Patient Enrollment For Phase I/IIa Trial Of Cethrin(R) In Treatment Of Acute Spinal Cord Injury
7/10/2006 10:35:51 AM
More...
|
BioAxone Therapeutic Inc. Announces Closing Of $5.1 Million
12/19/2005 10:26:22 AM
More...
|
BioAxone Therapeutic Inc. Release: Cethrin(R) Receives Orphan Drug Status
12/12/2005 12:09:25 PM
More...
|
BioAxone Therapeutic Inc. Appoints Patrick Tremblay Vice President Research & Development
11/29/2005 10:44:39 AM
More...
|
BioAxone Therapeutic Inc. Announces First Patient Treatment In Acute Spinal Cord Injury Trial
10/19/2005 5:12:38 PM
More...
|
BioAxone Therapeutic Inc. Announces A Second-Round Investment Of $12.15 Million
10/19/2005 5:09:54 PM
More...
|